Skip to content

Time left to comment:

Day
Hour
Minute
Second

Interchange 2014 Highlights: Retired FDA-OCI Assistant Director Jim Dahl Speaks about the Impact of the Counterfeit Drug Problem in the U.S.

At PSM’s 2014 Interchange, Jim Dahl, a 30 year veteran of Federal law enforcement, spoke about the scale of the counterfeit drug problem in the United States and how much risk Americans should be willing to accept.

jimAt PSM’s 2014 Interchange, Jim Dahl, a 30 year veteran of Federal law enforcement, spoke about the scale of the counterfeit drug problem in the United States and how much risk Americans should be willing to accept.

PSM board member Jim Dahl is a 30 year veteran of Federal law enforcement and spent his last nine years in government as the Assistant Director of the FDA’s Office of Criminal Investigations. We were fortunate to have Jim moderate our fourth panel, “How the Black Market Impacts Patients,” at PSM’s 2014 Interchange, where he discussed the scale of the counterfeit drug problem in the United States:

We certainly still have the gold standard of a drug delivery system here in the United States, but one in six Americans buys drugs on the Internet without a prescription, and that’s a cause for danger as we’ve heard from our previous panel…What is the acceptable risk? What should we be willing to accept? I would submit to you that when it comes to prescription drugs, the acceptable risk is 0. We shouldn’t accept any risk.

You can hear all of Jim’s remarks, as well as the entire panel by watching the YouTube video embedded below, and see his presentation slides in PSM’s slideshare collection.

By S. Imber

Scroll To Top